The present study was carried out to examine the predictive value of endocrine profiles as indicators of the sperm retrieval rate on testicular sperm extraction (TESE) in azoospermic men.
INTRODUCTION
A ZOOSPERMIA IS THE most severe form of male infertility. In the past, it was not possible for azoospermic patients to father their own children and they had to resort to the only measure available to them, which was artificial insemination with donor spermatozoa. Recently, however, fertilization can be achieved by injecting a spermatozoon into the cytoplasm of an oocyte with a micromanipulator. This method, known as intracytoplasmic sperm injection (ICSI), has made remarkable progress 1 and, thus, it is now possible to fertilize an oocyte with just a single spermatozoon. Pregnancy is achieved through the following set of procedures: (i) surgical extraction of the testicular tissue from the azoospermic patient; (ii) retrieval of testicular spermatozoa under the microscope; and (iii) fertilization with ICSI.
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The sperm recovery rate from the testicular sperm extraction (TESE) procedure ranges from 40 to 60% 3 and it is often the case that no spermatozoon can be recovered from patients with atrophied testes. However, at present there is still no treatment for azoospermia itself and TESE-ICSI is the only option available that offers azoospermic patients the possibility of fathering children with their own genetic material. As such, despite the knowledge that half of the cases will result in failure, patients still opt to try TESE. The present study examines some non-invasive measures of predicting the presence or absence of testicular spermatozoa in azoospermic men before TESE.
METHODS

Patients and study design
T HE POPULATION COMPRISED 43 azoospermic patients who were thoroughly briefed about the procedures and consented to them. The patients underwent semen analyses more than three times and those whose semen contained no spermatozoon every time were classified as azoospermic. The etiologies of *Correspondence: Masao Jinno, President, Women's Clinic Jinno, 3-1-39-201, Kokuryou-chou, Choufu City, Tokyo 182-0022, Japan. Email: mjinno@sq.dion.ne.jp Received 16 May 2005; accepted 30 June 2005. azoospermia were idiopathic azoospermia (35 cases), azoospermia secondary to cryptorchidism (two cases), obstructive azoospermia (three cases) and others (three cases: congenital abnormality and ejaculatory disorder resulting from spinal cord trauma). The mean age (SEM) of patients was 36.4 ± 1.0 years.
A month before carrying out TESE, the serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), testosterone (T), dihydrotestosterone (DHT), estradiol (E 2 ) and 17 α-hydroxyprogesterone (17 α-OHP) were measured. Using ultrasound tomography, the sagittal cross-section area of the testes was also measured. Following the retrieval of testicular spermatozoa on TESE, ICSI was subsequently carried out. Furthermore, the correlations between etiology, serum hormone levels and sagittal cross-section area to the presence or absence of testicular sperm were analyzed.
Ultrasound scanning of the testis and serum hormone level measurements
Ultrasonography of the testes of azoospermic patients was carried out by grasping the scrotum and applying a 7.5 MHz transvaginal sonographic probe (GE Yokogawa Medical Systems, Tokyo, Japan) from the direction of the feet upward to acquire a sagittal cross-section image of the testis. The largest possible image of the sagittal cross-section area was obtained and the area was traced and automatically measured. The testicular sagittal area was defined as the sum of the maximum sagittal crosssection areas of the left and right testes.
Radioimmunoassay (RIA) was used to measure the serum FSH, PRL, 17 α-OHP, T, DHT and E 2 levels (Spack-S FSH and Spack-S PRL, Daiichi Radioisotope Laboratories, Tokyo, Japan; DPC 17 α-OH-Progesterone Kit, DPC Total Testosterone Kit, DPC Dihydrotestosterone Kit and DPC Estradiol Kit, Diagnostics Products, Los Angeles, CA, USA). As for serum LH level, it was measured using enzyme immunoassay (Immulyze LH; Diagnostics Products). The sensitivity, and the intra-and interassay coefficients of variation were found to be 0.5 IU/L, 4.0% and 3.0% for FSH; 0.7 IU/L, 6.2% and 5.5% for LH; 1.0 ng/mL, 6.3% and 6.9% for PRL; 0.07 ng/mL, 10.2% and 9.4% for 17 α-OHP; 4 ng/mL, 6.1% and 8.3% for T; 0.019 ng/mL, 7.6% and 14.6% for DHT; and 10 pg/mL, 5.6% and 6.8% for E 2 , respectively.
Testicular sperm extraction
A vertical incision of approximately 1 cm was made in the scrotal skin up to the tunica albuginea. The testis was fixed during the incision by passing a thread through it. While holding the testes with one hand, applying pressure on the testicular tissue and at the same time slightly pulling with forceps, the protruding testicular tissue was excised. The tunica albuginea and the scrotal skin were closed with 3-0 Vicryl stitches. The collected testicular tissue was placed in a culture dish (Falcon 3002; Becron Dickinson Labware, Franklin Lakes, NJ, USA) containing HTF medium supplemented with 10% serum. Dissection of the testicular tissue was carried out under a stereomicroscope using an ophthalmic blade and a 27G needle and the contents of the seminiferous tubules were pushed out. The extracted tissue suspension was centrifuged and resuspended in 1 mL of HTF medium supplemented with 10% serum. This testicular sample was checked for the presence of spermatozoa under a microscope at ×200-400 magnifications. Using the pipette for sperm injection in ICSI, the retrieved sperm were collected into a droplet. After obtaining an amount comparable to the number of oocytes, ICSI was initialized. The spermatozoa for injection were transferred to the ICSI droplet and after washing well, they were immobilized (regardless of the sperm motility).
Ovarian stimulation
Stimulations of the ovaries were carried out using either the long protocol (L protocol) of gonadotropin-releasing hormone (GnRH) agonist and human menopausal gonadotropin (hMG) regimen or the bromocriptinerebound method (BR method).
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In the L protocol, nasal administration of buserelin (Suprecur, 900 µg/day; Hoechst, Tokyo, Japan) was started on day 4 of the high phase. Ovarian suppression was confirmed by a serum E 2 level of <20 pg/mL and the absence of ovarian follicles greater than 12 mm in diameter on transvaginal sonography. Daily intramuscular administration of three ampules of hMG (Pergonal, Teikoku Zouki, Tokyo; 75 IU LH plus 75 IU FSH in each ampule) was started. When the serum E 2 level exceeded 400 pg/ mL and the leading follicle was greater than 14 mm in diameter, the dosage of hMG was reduced to two ampules per day. Buserelin and hMG administration were discontinued and 10 000 IU hCG was given intramuscularly when the diameter of the leading follicle reached 17-19 mm and the serum E 2 level was above 400 pg/mL. Thirty-six hours after hCG administration, the oocytes were retrieved by puncturing the follicle and aspirating the contents under transvaginal ultrasound guidance.
In the BR method, bromocriptine (Parlodel, Sandoz, Tokyo) was given orally before going to sleep from
